KALA BIO, INC. Payments of Stock Issuance Costs
KALA BIO, INC. (KALA) reported Payments of Stock Issuance Costs of $866.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-04-15
- KALA BIO, INC. payments of stock issuance costs for the quarter ending 2017-06-30 was $765.00K.
- KALA BIO, INC. payments of stock issuance costs for the quarter ending 2017-03-31 was $19.00K.
- KALA BIO, INC. payments of stock issuance costs for the quarter ending 2016-12-31 was $0.00.
- KALA BIO, INC. payments of stock issuance costs for the quarter ending 2016-09-30 was $0.00.
- KALA BIO, INC. payments of stock issuance costs for fiscal 2025 was $866.00K, a 297.25% increase from fiscal 2024.
- KALA BIO, INC. payments of stock issuance costs for fiscal 2024 was $218.00K.
- KALA BIO, INC. payments of stock issuance costs for fiscal 2016 was $283.00K, a 81.21% decline from fiscal 2015.
- KALA BIO, INC. payments of stock issuance costs for fiscal 2015 was $1.51M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $866.00K 10-K · filed 2026-04-15 | |||
| 2024-12-31 | $218.00K 10-K · filed 2026-04-15 | |||
| 2018-09-30 | $163.00K 10-Q · filed 2019-11-07 | |||
| 2017-06-30 | $765.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $784.00K 10-Q · filed 2018-08-09 | $784.00K derived: sum of 3 quarters · filed 2018-08-09 | $784.00K derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $19.00K 10-Q · filed 2018-05-10 | $19.00K derived: sum of 2 quarters · filed 2018-05-10 | $19.00K derived: sum of 3 quarters · filed 2018-05-10 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $0.00 derived: sum of 2 quarters · filed 2018-04-02 | $283.00K 10-K · filed 2018-04-02 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $283.00K 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $283.00K 10-Q · filed 2017-08-31 | |||
| 2015-12-31 | $1.51M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |